Proton pump inhibitors in pediatrics : mechanism of action, pharmacokinetics, pharmacogenetics, and pharmacodynamics.
about
Human P450-like oxidation of diverse proton pump inhibitor drugs by 'gatekeeper' mutants of flavocytochrome P450 BM3Adverse effects reported in the use of gastroesophageal reflux disease treatments in children: a 10 years literature reviewDose-Finding Study of Omeprazole on Gastric pH in Neonates with Gastro-Esophageal Acid Reflux Using a Bayesian Sequential ApproachPantoprazole, a proton pump inhibitor, increases orthodontic tooth movement in ratsProton pump inhibitor for non-erosive reflux disease: a meta-analysis.Proton pump inhibitor-induced Sweet's syndrome: report of acute febrile neutrophilic dermatosis in a woman with recurrent breast cancerDietary intake and bio-activation of nitrite and nitrate in newborn infants.AroER tri-screen™ is a novel functional assay to estimate both estrogenic and estrogen precursor activity of chemicals or biological specimens.The use of proton pump inhibitors decreases the risk of diabetes mellitus in patients with upper gastrointestinal disease: A population-based retrospective cohort studyManagement of paediatric GERD.Esophagitis in children: an update on current pharmacotherapy.Pediatric perspective on pharmacogenomics.Safety of medication options for treating pediatric esophagitis.Safety of proton pump inhibitors and risk of gastric cancers: review of literature and pathophysiological mechanisms.Guidelines for proton pump inhibitor prescriptions in paediatric intensive care unit.Effects of Genetic Polymorphisms of Cytochrome P450 Enzymes and MDR1 Transporter on Pantoprazole Metabolism and Helicobacter pylori Eradication.Helicobacter pylori treatment in children: defining a dose for rabeprazole as a part of a triple therapy regimen.Pharmacogenomic testing: the case for CYP2C19 proton pump inhibitor gene-drug pairs.Efficacy of proton pump inhibitors and H2 blocker in the treatment of symptomatic gastroesophageal reflux disease in infants.Safety, dosing, and pharmaceutical quality for studies that evaluate medicinal products (including biological products) in neonates.Developmental pharmacogenetics of CYP2C19 in neonates and young infants: omeprazole as a probe drug.Association between CYP2C19 extensive metabolizer phenotype and childhood anti-reflux surgery following failed proton pump inhibitor medication treatment.Rethinking the Combination of Proton Exchanger Inhibitors in Cancer Therapy.Obese Children Require Lower Doses of Pantoprazole Than Nonobese Peers to Achieve Equal Systemic Drug Exposures.Cross-Reactivity of Pantoprazole with Three Commercial Cannabinoids Immunoassays in Urine.Predictive Performance of Physiologically Based Pharmacokinetic (PBPK) Modeling of Drugs Extensively Metabolized by Major Cytochrome P450s in Children.Population pharmacokinetics of rabeprazole and dosing recommendations for the treatment of gastroesophageal reflux disease in children aged 1-11 years.Effects of Esophageal Acidification on Troublesome Symptoms: An Approach to Characterize True Acid GERD in Dysphagic Neonates.Pantoprazole decreases gastroesophageal muscle tone in newborn rats via rho-kinase inhibition.Proton pump inhibitors: from CYP2C19 pharmacogenetics to precision medicine.Association between Proton Pump Inhibitor Use and CNS Infection Risk: A Retrospective Cohort Study
P2860
Q27689400-436C36F9-1C12-4C58-ADBE-6F881EE681FAQ28082238-626BD2A0-838E-4F25-9A19-507F24A8DBBFQ28555174-B569E9DD-6754-4FA6-A1C0-914474B16E38Q34065780-0483D8E5-CF38-452A-B146-7C32DC5DA375Q35074278-0547C839-4924-4162-980F-DD9FCFB6BF74Q35717639-15430E01-370A-46DE-8C93-232B2B665103Q35835549-6B241DF5-D5EB-4869-A460-507BAAE378F7Q36112971-B64818C7-DAAA-4984-9A00-3B3FD7D8EEF1Q37116878-BE978341-567F-48D4-875C-DCA2B0883A6DQ38152645-C7C2A5D7-A129-4553-8C4D-D4923DB6DB0FQ38153767-982A57C8-D0C3-48EA-B990-A20A5DE5A87AQ38162869-7B77BE6C-0F1F-42BC-813B-95CA04D97ED5Q38442609-434EEBB1-935A-48A1-9FD6-C6BFC80C52F2Q38631128-D4753C65-E748-47B3-898B-49F2D1775245Q40378224-060C1AC9-BA69-4E06-82EF-674CB56429AEQ40471212-E86E8A22-97D1-4328-92FC-7ABE669EC442Q41511330-2268AE61-7CCB-4292-A998-19112A729459Q41706384-5968B475-22CC-4017-BE45-9DE20B2B6DBCQ42063228-1BF7646C-5914-4061-9B15-B27AFFDDB5DCQ47428031-B2835391-BB9E-40DB-A8F9-652204B9A2B5Q48151911-4A300E3F-8C3B-4C7C-A47F-6296B5964890Q48170836-2CFBA2C1-4E0B-4479-B9A4-0FC8B3046DE0Q48552373-1CF5F36A-7F7E-48E4-99D1-A7DDD3F1241AQ49493799-DA3AFF11-FA00-4013-A7D4-5041C6650F68Q49556928-F93C831E-4067-4D99-A502-CC9534B94F23Q50062507-FB3EB7AA-B828-485A-9682-C0922E2E50BCQ50450387-0D1DD19F-BB36-47D7-9DE0-2BF335937504Q53387244-3A65EFD7-DCBD-4DCE-A3B8-D9A76B0E9077Q54362624-29D9E9E8-D8BF-47AB-9C7E-66BD2F52809CQ55280841-ED8F6FE2-092F-44A4-A9A5-90FE5D4C2892Q58779200-D4486B59-EE13-4F26-A311-CBEB53498B7E
P2860
Proton pump inhibitors in pediatrics : mechanism of action, pharmacokinetics, pharmacogenetics, and pharmacodynamics.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Proton pump inhibitors in pedi ...... enetics, and pharmacodynamics.
@en
type
label
Proton pump inhibitors in pedi ...... enetics, and pharmacodynamics.
@en
prefLabel
Proton pump inhibitors in pedi ...... enetics, and pharmacodynamics.
@en
P2860
P1433
P1476
Proton pump inhibitors in pedi ...... enetics, and pharmacodynamics.
@en
P2093
Gregory L Kearns
Robert M Ward
P2860
P2888
P304
P356
10.1007/S40272-013-0012-X
P577
2013-04-01T00:00:00Z
P5875
P6179
1030705126